MARKET

AVDL

AVDL

Avadel
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.48
+0.24
+2.91%
Closed 18:39 08/06 EDT
OPEN
8.55
PREV CLOSE
8.24
HIGH
8.87
LOW
8.39
VOLUME
656.12K
TURNOVER
--
52 WEEK HIGH
13.49
52 WEEK LOW
1.820
MARKET CAP
492.93M
P/E (TTM)
-10.8232
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AVDL stock price target is 18.25 with a high estimate of 23.00 and a low estimate of 15.00.

EPS

AVDL News

More
Oppenheimer: These 3 “Strong Buy” Stocks Could See 120% Gains, If Not More
The “dog days” of summer are here, but it’s just as busy as ever on the Street. As earnings results continue to roll in, investors will be watching for any update on the next economic stimulus package along with the non-farm payroll report slated for release t
TipRanks · 1d ago
Harmony Biosciences Starts U.S. IPO Effort
Seeking Alpha · 6d ago
Avadel Pharmaceuticals started at outperform with $19 stock price target at Oppenheimer
marketwatch.com · 07/31 08:27
Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th
DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Company'
GlobeNewswire · 07/27 12:00
Avadel Pharmaceuticals Announces First Patient Dosed In Open-Label Extension/Switch Study Of Investigation FT218 As Potential Treatment For Excessive Daytime Sleepiness, Cataplexy In Patients With Narcolepsy
Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with
Benzinga · 07/13 12:07
Avadel Pharmaceuticals Announces First Patient Dosed In Open-Label Extension/Switch Study Of Investigational Once-Nightly FT218 As A Potential Treatment For Excessive Daytime Sleepiness And Cataplexy In Patients With Narcolepsy
Clinical study to enroll 250 patients from sites that participated in the REST-ON study   Study to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for
Benzinga · 07/13 12:02
Jazz Pharmaceuticals: Buy, Sell, Or Hold
Seeking Alpha - Article · 07/09 17:00
Bearish: Analysts Just Cut Their Avadel Pharmaceuticals plc (NASDAQ:AVDL) Revenue and EPS estimates
Simply Wall St. · 07/03 12:05

Industry

Pharmaceuticals
-0.28%
Pharmaceuticals & Medical Research
-0.46%

Hot Stocks

Symbol
Price
%Change

About AVDL

Avadel Pharmaceuticals plc is a biopharmaceutical company. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
More

Webull offers kinds of Avadel Pharmaceuticals PLC (ADR) stock information, including NASDAQ:AVDL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVDL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVDL stock methods without spending real money on the virtual paper trading platform.